Fisher Asset Management LLC Sells 65,153 Shares of Novo Nordisk A/S (NYSE:NVO)

Fisher Asset Management LLC lessened its holdings in Novo Nordisk A/S (NYSE:NVO) by 0.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 13,305,474 shares of the company’s stock after selling 65,153 shares during the quarter. Fisher Asset Management LLC owned 0.30% of Novo Nordisk A/S worth $1,584,283,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. 1620 Investment Advisors Inc. acquired a new stake in shares of Novo Nordisk A/S in the second quarter valued at about $25,000. Strategic Investment Solutions Inc. IL bought a new position in Novo Nordisk A/S in the second quarter valued at approximately $25,000. Gilliland Jeter Wealth Management LLC increased its position in shares of Novo Nordisk A/S by 200.0% during the 2nd quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock worth $26,000 after purchasing an additional 120 shares during the last quarter. Daiwa Securities Group Inc. bought a new stake in shares of Novo Nordisk A/S during the 3rd quarter worth approximately $28,000. Finally, Halpern Financial Inc. boosted its holdings in shares of Novo Nordisk A/S by 113.0% in the 2nd quarter. Halpern Financial Inc. now owns 213 shares of the company’s stock valued at $30,000 after buying an additional 113 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Performance

NYSE NVO opened at $105.06 on Monday. The stock has a market cap of $471.46 billion, a PE ratio of 34.00, a P/E/G ratio of 1.35 and a beta of 0.42. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. The firm has a 50-day moving average of $115.48 and a 200-day moving average of $128.81. Novo Nordisk A/S has a 52-week low of $94.73 and a 52-week high of $148.15.

Wall Street Analyst Weigh In

Several analysts have issued reports on NVO shares. BMO Capital Markets dropped their price target on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a research report on Thursday, October 17th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. Finally, StockNews.com upgraded Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a report on Friday, November 1st. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $144.50.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.